Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Original Article
Intensive care unit: mortality score in early prediction of mortality in critical COVID-19 patients
Aims: The mortality data available in the literature with regard to patients with SARS-COV-2, thus requiring hospitalization in the intensive care unit (ICU) are not sufficient. This research aims to compare the correlation between COVID-19 mortality ratios (CMR), AST/ALT and neutrophil/lymphocyte (N/L) ratios of non-smoker COVID-19 patients hospitalized in the ICU and their mortality rates. Methods: This cross-sectional study was conducted on 77 patients hospitalized in the ICU. Female participants constituted 64.9% (n=50) of the study group while male made up 35.1% (n=27); the mean age was 61.3±14.3 and 66.2% (n=51) of the patients died. To exclude the adverse effect of smoking on mortality, patients were confirmed to be non-smokers by analyzing the cotinine levels in urine samples. For this purpose, patients’ age, gender, comorbidities, fever, pulse, blood pressure, saturation values, APACHE scores and biochemical parameters were evaluated. Results: In the study, 66.2% (n=51) of the patients died during follow-up. Age, urea, creatinine, AST/ALT, N/L ratio and CMR values of the nonsurvivors were significantly higher than those of the survivors. The systolic blood pressure and lymphocyte values of non-survivors were lower than survivors. Conclusions: The conclusion of the study revealed that CMR scores, AST/ALT levels and the N/L ratio can effectively be utilized in early period to project the mortality rates of non (active) smoking patients with critical COVID-19 infection hospitalized in the ICU.

1. Salah HM, Sharma T, Mehta J. Smoking doubles the mortalityrisk in COVID-19: a meta-analysis of recent reports andpotential mechanisms. Cureus. 2020;12(10):e10837. doi: 10.7759/cureus.10837
2. Wu Z, McGoogan JM. Characteristics of and important lessonsfrom the coronavirus disease 2019 (COVID-19) outbreakin China: summary of a report of 72 314 cases from theChinese Center for disease control and prevention. JAMA.2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
3. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 amongchildren in China. Pediatrics. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702.
4. Barda N, Riesel D, Akriv A, et al. Developing a COVID-19mortality risk prediction model when individual-level dataare not available. Nat Commun. 2020;11(1):4439. doi: 10.1038/s41467-020-18297-9.
5. Imran A, Posokhova I, Qureshi HN, et al. AI4COVID-19: AIenabled preliminary diagnosis for COVID-19 from coughsamples via an app. Inform Med Unlocked. 2020;20:100378. doi:10.1016/j.imu.2020.100378.
6. Abdulaal A, Patel A, Charani E, Denny S, Mughal N, Moore L.Prognostic modeling of COVID-19 using artificial intelligence inthe United Kingdom: model development and validation. J MedInternet Res. 2020;22(8):e20259. doi: 10.2196/20259.
7. Bertsimas D, Lukin G, Mingardi L, et al. COVID-19 mortalityrisk assessment: An international multi-center study. PLoS One.2020;15(12):e0243262. doi: 10.1371/journal.pone.0243262.
8. Chen T, Guestrin C. XGBoost: a scalable tree boosting system.proceedings of the ACM SIGKDD international conference onknowledge discovery and data mining. 2016.pp.785-794.
9. Epidemiology Working Group for NCIP Epidemic Response,Chinese Center for Disease Control and Prevention. [Theepidemiological characteristics of an outbreak of 2019 novelcoronavirus diseases (COVID-19) in China]. Zhonghua Liu XingBing XueZaZhi. 2020;41(2):145-151. Chinese.
10. Parascandola M, Xiao L. Tobacco and the lung cancer epidemicin China. Transl Lung Cancer Res. 2019;8(Suppl 1):S21-30.
11. Shastri MD, Shukla SD, Chong WC, et al. Smoking andCOVID-19: What we know so far. Respir Med. 2021;176:106237.doi: 10.1016/j.rmed.2020.106237
12. Zhao Q, Meng M, Kumar R, et al. The impact of COPD andsmoking history on the severity of COVID-19: a systemic reviewand meta-analysis. J Med Virol. 2020;92(10):1915-1921. doi:10.1002/jmv.25889.
13. COVID Analytics. Analytics can calculate the risk of mortality.2023 Available at:
14. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severeCOVID-19 disease with ACE inhibitors and angiotensin receptorblockers: cohort study including 8.3 million people. Heart.2020;106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393.
15. Saadatian-Elahi M, Amour S, Elias C, Henaff L, DananchéC, Vanhems P. Tobacco smoking and severity of COVID-19:experience from a hospital-based prospective cohort study inLyon, France. J Med Virol. 2021;93(12):6822-6827. doi: 10.1002/jmv.27233.
16. Jackson SE, Brown J, Shahab L, Steptoe A, Fancourt D.COVID-19, smoking and inequalities: a study of 53 002 adultsin the UK. Tob Control. 2021;30(e2):e111-e121. doi: 10.1136/tobaccocontrol-2020-055933.
17. Patanavanich R, Glantz SA. Smoking is associated withCOVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22(9):1653-1656.
18. Clift AK, von Ende A, Tan PS, et al. Smoking and COVID-19outcomes: an observational and Mendelian randomisation studyusing the UK Biobank cohort. Thorax. 2022;77(1):65-73. doi:10.1136/thoraxjnl-2021-217080.
19. Choi JW. Association between smoking status and death fromCOVID-19 in South Korea: a nationwide cohort study. Tob InducDis. 2023;21:97. doi: 10.18332/tid/168672.
20. Zhang H, Ma S, Han T, et al. Association of smoking history withsevere and critical outcomes in COVID-19 patients: A systemicreview and meta-analysis. Eur J Integr Med. 2021;43:101313. doi:10.1016/j.eujim.2021.101313.
21. Gallus S, Scala M, Possenti I, et al. The role of smoking inCOVID-19 progression: a comprehensive meta-analysis. EurRespir Rev. 2023;32(167):220191. doi: 10.1183/16000617.0191-2022.
22. Elliott J, Bodinier B, Whitaker M, et al. COVID-19 mortality inthe UK Biobank cohort: revisiting and evaluating risk factors.Eur J Epidemiol. 2021;36(3):299-309. doi: 10.1007/s10654-021-00722-y.
23. Sun B, Wang H, Lv J, Pei H, Bai Z. Predictors of mortality inhospitalized COVID-19 patients complicated with hypotensionand hypoxemia: a retrospective cohort study. Front Med(Lausanne). 2021;8:753035. doi: 10.3389/fmed.2021.753035.
24. Lacedonia D, Scioscia G, Santomasi C, et al. Impact of smoking,COPD and comorbidities on the mortality of COVID-19 patients.Sci Rep. 2021;11(1):19251. doi: 10.1038/s41598-021-98749-4.
25. Taramasso L, Vena A, Bovis F, et al. Higher mortality andintensive care unit admissions in COVID-19 patients withliver enzyme elevations. Microorganisms. 2020;8(12):2010. doi:10.3390/microorganisms8122010.
26. Lei F, Liu YM, Zhou F, et al. Longitudinal association betweenmarkers of liver injury and mortality in COVID-19 in China.Hepatology. 2020;72(2):389-398. doi: 10.1002/hep.31301.
27. Fu J, Kong J, Wang W, et al. The clinical implication of dynamicneutrophil to lymphocyte ratio and D-dimer in COVID-19: aretrospective study in Suzhou China. Thromb Res. 2020;192:3-8.doi: 10.1016/j.thromres.2020.05.006
28. Huang C, Wang Y, Li X, et al. Clinical features of patientsinfected with 2019 novel coronavirus in Wuhan, China. Lancet.2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
29. Uğur Chousein EG, Çörtük M, Cınarka H, et al. Is there anyeffect of smoking status on severity and mortality of hospitalizedpatients with COVID-19 pneumonia? Tuberk Toraks.2020;68(4):371-378. doi: 10.5578/tt.70352
30. Taylor EH, Marson EJ, Elhadi M, et al. Factors associated withmortality in patients with COVID-19 admitted to intensivecare: a systematic review and meta-analysis. Anaesthesia.2021;76(9):1224-1232. doi: 10.1111/anae.15532
31. Mahabee-Gittens EM, Mendy A, Merianos AL. Assessmentof Severe COVID-19 Outcomes Using Measures of SmokingStatus and Smoking Intensity. Int J Environ Res Public Health.2021;18(17):8939.
32. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, KhajuriaA. The effect of smoking on COVID-19 severity: A systematicreview and meta-analysis. J Med Virol. 2021;93(2):1045-1056. doi:10.1002/jmv.26389
Volume 4, Issue 5, 2023
Page : 572-578